{"nctId":"NCT01281007","briefTitle":"Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes","startDateStruct":{"date":"2012-07"},"conditions":["GENITAL HERPES"],"count":150,"armGroups":[{"label":"Famciclovir 125 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Famciclovir"]},{"label":"Aciclovir 200 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Aciclovir"]}],"interventions":[{"name":"Famciclovir","otherNames":[]},{"name":"Aciclovir","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Patients must be able to understand the study procedures agree to participate and give written consent.\n2. Patients with clinical diagnosis of recurrent genital herpes;\n3. Score symptoms higher than 4;\n4. Negative pregnant urine test.\n\nExclusion criteria:\n\n1. Pregnancy or risk of pregnancy.\n2. Lactation\n3. Any pathology or past medical condition that can interfere with this protocol.\n4. Non-steroidal anti-inflammatory drug , hormonal anti-inflammatory or immunosuppressive drugs (in the last 30 days and during the study);\n5. Patients with immunodeficiency and/or immunosuppressive disease;\n6. Hypersensitivity to components of the formula;\n7. Other conditions deemed reasonable by the medical investigator as to the disqualification of the individual from study participation.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Efficacy Will be Evaluated by the Proportion of Subjects With Non Herpes Manifestation","description":"Symptoms evaluated: erythema, papule, vesicle, ulcer, crust, or healed skin.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety Will be Evaluated by the Adverse Events Occurence","description":"Adverse events will be collected and followed in order to evaluate safety and tolerability","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":75},"commonTop":["Headache"]}}}